Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •Histologically confirmed metastatic solid tumor for which there are no effective standard treatment options
• •HER2 positive (1+ to 3+)
• •Tumor has a high likelihood of expressing epidermal growth factor receptor (EGFR)
• •No evidence of leptomeningeal disease or brain metastases unless previously treated, currently asymptomatic, and off both antiepileptics and dexamethasone
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •At least 12 weeks
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin normal
• •AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver has tumor involvement)
• •Creatinine normal
• •Creatinine clearance at least 60 mL/min
• •LVEF more than 50% by radionuclide ventriculogram or MUGA scan
• •No significant cardiovascular disease
• •No prior congestive heart failure requiring therapy
• •No unstable angina pectoris
• •No myocardial infarction within the past 6 months
• •No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• •* Patients who are unable to swallow tablets and/or who have silicon-based G-tubes may dissolve the tablets in distilled water
• •No active peptic ulcer disease
• •HIV negative
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No known or suspected hypersensitivity to paclitaxel
• •No prior allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or other study agents
• •No concurrent active infection
• •No other concurrent medical condition that would preclude study participation
• •No persistent grade 2 or greater neurotoxicity/neuropathy from any cause
• •No psychiatric disorders or altered mental status that would preclude study participation
• •No other concurrent immunotherapy
• •No concurrent cytokine growth factors (e.g., colony-stimulating factors)
• •At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
• •No other concurrent chemotherapy
• •See Disease Characteristics
• •No concurrent hormonal therapy except megestrol as an appetite stimulant or luteinizing hormone-releasing hormone agonists for prostate cancer
• •See Disease Characteristics
• •No concurrent radiotherapy
• •No prior surgical procedures affecting absorption
• •No prior EGFR-targeting therapy
• •No other concurrent experimental medications or other specific antitumor therapy
• •No concurrent immunosuppressant therapy
• •No concurrent antiarrhythmic therapy for a ventricular arrhythmia